Survival Benefit for Patients with Hepatocellular Carcinoma -- A Population Based Study
Principal Investigator
Name
Hua Tiantian
Degrees
M.P.H.
Institution
Department of Epidemiology and Biostatistics, School of Public Health, Southeast University
Position Title
None
Email
About this CDAS Project
Study
PLCO
(Learn more about this study)
Project ID
PLCO-465
Initial CDAS Request Approval
Apr 2, 2019
Title
Survival Benefit for Patients with Hepatocellular Carcinoma -- A Population Based Study
Summary
Incidence and mortality rates of hepatocellular carcinoma (HCC) have been increasing in almost all age groups of the population worldwide. In recent years, several efforts have been made to improve HCC-mediated mortality, including the development of direct antiviral drugs for HCV, the implementation of secondary prevention screening programs, the application of algorithms for therapy stratification and the improvement of local and surgical therapies. We want to know whether and to which extent these advances have translated into a clinical benefit in the general population.
Aims
To assess whether the implementation of screening policies and the improvement of treatment options have already been translated into a real-world survival benefit in HCC patients.
Collaborators
Xuesi Dong, Department of Biostatistics, School of Public Health, Nanjing Medical University